Company Profile
IN8bio Stock Price, News & Analysis
Company overview
Business overview
IN8bio is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, IN8bio is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
IN8bio follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, IN8bio sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
INAB is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
IN8bio is still very much tied to its DeltEx γδ T-cell programs, especially the glioblastoma work. The survival data and the favorable safety profile matter because they are the kind of signals that can keep a cell-therapy platform credible while the company pushes the program forward.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.